Welch & Forbes LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 718,331 shares of the company’s stock after purchasing an additional 6,730 shares during the quarter. Johnson & Johnson comprises about 2.7% of Welch & Forbes LLC’s investment portfolio, making the stock its largest holding. Welch & Forbes LLC’s holdings in Johnson & Johnson were worth $95,028,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. State Street Corp grew its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC grew its stake in Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the period. Korea Investment CORP grew its stake in Johnson & Johnson by 38.9% in the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after acquiring an additional 596,134 shares during the period. Bank of Nova Scotia grew its stake in Johnson & Johnson by 94.5% in the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after acquiring an additional 569,313 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in Johnson & Johnson in the first quarter valued at about $65,598,000. Institutional investors and hedge funds own 66.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-welch-forbes-llc/1697112.html.

JNJ has been the subject of a number of research analyst reports. UBS AG reissued a “buy” rating and issued a $148.00 target price (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets reissued a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $143.70.

Shares of Johnson & Johnson (NYSE JNJ) opened at $139.56 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The stock has a market capitalization of $374,930.72, a P/E ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.68 earnings per share. equities research analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio is 58.33%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.